The management of hiv-hodgkin lymphoma

Marcus Hentrich; Michele Spina

doi:10.1007/978-3-030-32482-7_19

The management of hiv-hodgkin lymphoma

Marcus Hentrich, Michele Spina

Centro di Riferimento Oncologico

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Hodgkin lymphoma (HL) is one of the most common non-AIDS-defining malignancies in the setting of HIV. Patients usually present with advanced-stage disease and median CD4 cell counts roughly between 150 and 250/μL. Since the introduction of combined antiretroviral therapy (cART), the prognosis of patients with HIV-HL has markedly improved. Standard curative-intent therapy and modern cART has resulted in outcomes that are similar to that reported in the general population.

Original language	English
Title of host publication	Hematologic Malignancies
Publisher	Springer
Pages	335-347
Number of pages	13
DOIs	https://doi.org/10.1007/978-3-030-32482-7_19
Publication status	Published - 2020

Publication series

Name	Hematologic Malignancies
ISSN (Print)	2197-9766
ISSN (Electronic)	2197-9774

Keywords

Autologous stem cell transplantation
Brentuximab vedotin
HIV
HIV-associated Hodgkin lymphoma
Hodgkin lymphoma

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1007/978-3-030-32482-7_19

Fingerprint Dive into the research topics of 'The management of hiv-hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this

@inbook{67634e1d5bf1462a95d7af56d8021a2b,

title = "The management of hiv-hodgkin lymphoma",

abstract = "Hodgkin lymphoma (HL) is one of the most common non-AIDS-defining malignancies in the setting of HIV. Patients usually present with advanced-stage disease and median CD4 cell counts roughly between 150 and 250/μL. Since the introduction of combined antiretroviral therapy (cART), the prognosis of patients with HIV-HL has markedly improved. Standard curative-intent therapy and modern cART has resulted in outcomes that are similar to that reported in the general population.",

keywords = "Autologous stem cell transplantation, Brentuximab vedotin, HIV, HIV-associated Hodgkin lymphoma, Hodgkin lymphoma",

author = "Marcus Hentrich and Michele Spina",

year = "2020",

doi = "10.1007/978-3-030-32482-7_19",

language = "English",

series = "Hematologic Malignancies",

publisher = "Springer",

pages = "335--347",

booktitle = "Hematologic Malignancies",

}

TY - CHAP

T1 - The management of hiv-hodgkin lymphoma

AU - Hentrich, Marcus

AU - Spina, Michele

PY - 2020

Y1 - 2020

N2 - Hodgkin lymphoma (HL) is one of the most common non-AIDS-defining malignancies in the setting of HIV. Patients usually present with advanced-stage disease and median CD4 cell counts roughly between 150 and 250/μL. Since the introduction of combined antiretroviral therapy (cART), the prognosis of patients with HIV-HL has markedly improved. Standard curative-intent therapy and modern cART has resulted in outcomes that are similar to that reported in the general population.

AB - Hodgkin lymphoma (HL) is one of the most common non-AIDS-defining malignancies in the setting of HIV. Patients usually present with advanced-stage disease and median CD4 cell counts roughly between 150 and 250/μL. Since the introduction of combined antiretroviral therapy (cART), the prognosis of patients with HIV-HL has markedly improved. Standard curative-intent therapy and modern cART has resulted in outcomes that are similar to that reported in the general population.

KW - Autologous stem cell transplantation

KW - Brentuximab vedotin

KW - HIV

KW - HIV-associated Hodgkin lymphoma

KW - Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85084196549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084196549&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-32482-7_19

DO - 10.1007/978-3-030-32482-7_19

M3 - Chapter

AN - SCOPUS:85084196549

T3 - Hematologic Malignancies

SP - 335

EP - 347

BT - Hematologic Malignancies

PB - Springer

ER -